Payment overview · 2025
General Payments
$1,287.07
67 reported records · 21 companies
Healthcare provider profile · identity verified
Arundhati Harati, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ARLINGTON, TX · NPI 1124085774
Verified facts
What the public records show
CMS Open Payments records show Arundhati Harati, MD received $1,287.07 in general payments during 2025 across 67 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $248.11 | 19.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $173.80 | 13.5% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $119.72 | 9.3% | 7 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $92.63 | 7.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.32 | 6.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.61 | 6.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.80 | 5.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.93 | 5.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.07 | 4.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.46 | 2.8% | 2 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.33 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.23 | 2.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.70 | 2.4% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $22.18 | 1.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.24 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.32 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.09 | 1.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.25 | 1.5% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.59 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.58 | 1.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.11 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,287.07 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $295.09 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $120.38 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $120.38 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $119.72 | 7 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $92.63 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.32 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.32 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.02 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.82 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.82 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $11.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 243 |
| Levothyroxine Sodium | Levothyroxine Sodium | 501 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 330 | 97 |
| Lisinopril | Lisinopril | 313 | 92 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 292 | 82 |
| Alprazolam | Alprazolam | 219 | 47 |
| Metformin Hcl | Metformin Hcl | 199 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 57 |
| Metformin Hcl Er | Metformin Hcl | 173 | 52 |
| Losartan Potassium | Losartan Potassium | 164 | 57 |
| Simvastatin | Simvastatin | 153 | 42 |
| Gabapentin | Gabapentin | 150 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 40 |
| Sertraline Hcl | Sertraline Hcl | 124 | 40 |
| Omeprazole | Omeprazole | 120 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 27 |
| Amoxicillin | Amoxicillin | 96 | 81 |
| Carvedilol | Carvedilol | 93 | 28 |
| Furosemide | Furosemide | 92 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 28 |
| Jardiance | Empagliflozin | 89 | 30 |
| Atenolol | Atenolol | 87 | 23 |
| Potassium Chloride | Potassium Chloride | 87 | 29 |
| Alendronate Sodium | Alendronate Sodium | 81 | 26 |
| Montelukast Sodium | Montelukast Sodium | 81 | 24 |
| Allopurinol | Allopurinol | 74 | 25 |
| Valsartan | Valsartan | 73 | 18 |
| Fenofibrate | Fenofibrate | 71 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 19 |
| Trazodone Hcl | Trazodone Hcl | 69 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 30 |
| Naproxen | Naproxen | 63 | 28 |
| Irbesartan | Irbesartan | 61 | 19 |
| Januvia | Sitagliptin Phosphate | 58 | 16 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 55 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 16 |
| Cephalexin | Cephalexin | 46 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Estradiol | Estradiol | 38 | 14 |
| Ozempic | Semaglutide | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | 18 |
| Glimepiride | Glimepiride | 36 | suppressed |
| Telmisartan | Telmisartan | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | 13 |
| Ezetimibe | Ezetimibe | 34 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Yuvafem | Estradiol | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,287.07 · 67 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Flector, Fluad, Flucelvax, Heplisav-B, JARDIANCE, Kerendia, Licart, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TZIELD, Tirosint, UBRELVY, VOQUEZNA, VYKAT XR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error